Insider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Sells 259 Shares of Stock

Key Points

• Lai Wang, an insider at BeOne Medicines, recently sold 259 shares of the company's stock for a total of $78,995.00, decreasing their position by 0.03% to 1,023,529 shares.
• BeOne Medicines has faced a negative net margin of 9.40% and analysts predict it will report earnings per share of -5.82 for the current year.
• The firm received multiple analyst upgrades, with Wall Street Zen raising its rating from "hold" to "buy" and new price targets set between $330.00 and $349.00 by various brokerages.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 259 shares of the stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $305.00, for a total value of $78,995.00. Following the transaction, the insider owned 1,023,529 shares in the company, valued at $312,176,345. This trade represents a 0.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Lai Wang also recently made the following trade(s):

• On Tuesday, July 29th, Lai Wang sold 4,041 shares of BeOne Medicines stock. The shares were sold at an average price of $302.49, for a total value of $1,222,362.09.
• On Friday, July 18th, Lai Wang sold 700 shares of BeOne Medicines stock. The shares were sold at an average price of $300.00, for a total value of $210,000.00.
• On Monday, June 23rd, Lai Wang sold 1,028 shares of BeOne Medicines stock. The shares were sold at an average price of $260.00, for a total value of $267,280.00.
• On Tuesday, June 17th, Lai Wang sold 470 shares of BeOne Medicines stock. The shares were sold at an average price of $251.37, for a total value of $118,143.90.
• On Monday, June 16th, Lai Wang sold 1,177 shares of BeOne Medicines stock. The shares were sold at an average price of $266.40, for a total value of $313,552.80.
• On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The shares were sold at an average price of $252.39, for a total value of $353,850.78.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC traded up $3.26 during midday trading on Monday, reaching $302.27. 129,620 shares of the company's stock were exchanged, compared to its average volume of 436,361. The stock has a 50 day moving average price of $263.99. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $33.13 billion, a PE ratio of -81.26 and a beta of 0.27. BeOne Medicines Ltd. - Sponsored ADR has a fifty-two week low of $158.84 and a fifty-two week high of $308.87.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. Equities research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new position in BeOne Medicines during the 2nd quarter valued at about $28,000. Farther Finance Advisors LLC purchased a new position in BeOne Medicines during the 2nd quarter valued at about $39,000. Signaturefd LLC purchased a new position in BeOne Medicines during the 2nd quarter valued at about $49,000. Parallel Advisors LLC purchased a new position in BeOne Medicines during the 2nd quarter valued at about $59,000. Finally, FNY Investment Advisers LLC purchased a new position in BeOne Medicines during the 2nd quarter valued at about $121,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. JPMorgan Chase & Co. increased their price objective on BeOne Medicines from $321.00 to $345.00 and gave the company an "overweight" rating in a research note on Thursday, July 17th. Guggenheim raised their target price on BeOne Medicines from $348.00 to $350.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Morgan Stanley raised their target price on BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a research note on Friday, June 27th. Royal Bank Of Canada raised their target price on BeOne Medicines from $311.00 to $349.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Finally, TD Securities reaffirmed a "buy" rating and issued a $334.00 target price on shares of BeOne Medicines in a research note on Thursday, April 24th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, BeOne Medicines currently has a consensus rating of "Buy" and an average price target of $327.56.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.